CareDx, Inc (CDNA)
CDNA Stock Price Chart
Explore CareDx, Inc interactive price chart. Choose custom timeframes to analyze CDNA price movements and trends.
CDNA Company Profile
Discover essential business fundamentals and corporate details for CareDx, Inc (CDNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
17 Jul 2014
Employees
644.00
Website
https://www.caredx.comCEO
John Walter Hanna Jr.
Description
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
CDNA Financial Timeline
Browse a chronological timeline of CareDx, Inc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is $0.13.
Earnings released on 6 Aug 2025
EPS came in at $0.10 falling short of the estimated $0.12 by -16.67%, while revenue for the quarter reached $86.68M , missing expectations by -9.00%.
Earnings released on 30 Apr 2025
EPS came in at $0.09 surpassing the estimated $0.06 by +50.00%, while revenue for the quarter reached $84.69M , beating expectations by +0.18%.
Earnings released on 26 Feb 2025
EPS came in at $0.18 surpassing the estimated $0.05 by +260.00%, while revenue for the quarter reached $86.58M , beating expectations by +2.39%.
Earnings released on 4 Nov 2024
EPS came in at $0.14 surpassing the estimated $0.01 by +1.30K%, while revenue for the quarter reached $82.88M , beating expectations by +0.88%.
Earnings released on 31 Jul 2024
EPS came in at $0.25 surpassing the estimated -$0.13 by +292.31%, while revenue for the quarter reached $92.27M , beating expectations by +15.99%.
Earnings released on 9 May 2024
EPS came in at -$0.03 surpassing the estimated -$0.19 by +84.21%, while revenue for the quarter reached $72.05M , beating expectations by +14.11%.
Earnings released on 28 Feb 2024
EPS came in at -$0.17 surpassing the estimated -$0.24 by +29.17%, while revenue for the quarter reached $65.57M , beating expectations by +3.01%.
Earnings released on 8 Nov 2023
EPS came in at -$0.18 surpassing the estimated -$0.38 by +52.63%, while revenue for the quarter reached $67.19M , beating expectations by +8.90%.
Earnings released on 8 Aug 2023
EPS came in at -$0.18 surpassing the estimated -$0.42 by +57.14%, while revenue for the quarter reached $70.30M , beating expectations by +13.83%.
Earnings released on 10 May 2023
EPS came in at -$0.11 falling short of the estimated -$0.07 by -57.14%, while revenue for the quarter reached $77.26M , missing expectations by -4.26%.
Earnings released on 27 Feb 2023
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $82.38M , beating expectations by +0.88%.
Earnings released on 3 Nov 2022
EPS came in at -$0.06 surpassing the estimated -$0.14 by +57.14%, while revenue for the quarter reached $79.36M , missing expectations by -3.95%.
Earnings released on 4 Aug 2022
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $80.63M , missing expectations by -1.49%.
Earnings released on 5 May 2022
EPS came in at -$0.13 falling short of the estimated -$0.05 by -160.00%, while revenue for the quarter reached $79.42M , beating expectations by +0.62%.
Earnings released on 24 Feb 2022
EPS came in at -$0.03 falling short of the estimated -$0.01 by -192.40%, while revenue for the quarter reached $79.22M , beating expectations by +2.89%.
Earnings released on 28 Oct 2021
EPS came in at $0.07 surpassing the estimated $0.01 by +483.33%, while revenue for the quarter reached $75.59M , beating expectations by +2.83%.
Earnings released on 29 Jul 2021
EPS came in at $0.11 surpassing the estimated $0.05 by +120.00%, while revenue for the quarter reached $74.19M , beating expectations by +9.49%.
Earnings released on 5 May 2021
EPS came in at $0.14 surpassing the estimated $0.01 by +2.70K%, while revenue for the quarter reached $67.40M , missing expectations by -90.74%.
Earnings released on 24 Feb 2021
EPS came in at $0.08 surpassing the estimated $0.02 by +272.09%, while revenue for the quarter reached $58.64M , missing expectations by -44.44%.
Earnings released on 29 Oct 2020
EPS came in at $0.10 surpassing the estimated -$0.06 by +266.67%, while revenue for the quarter reached $53.37M , beating expectations by +150.00%.
CDNA Stock Performance
Access detailed CDNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.